| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $999,993 ) |
| | 2025 | 2025 | VERSATOPE THERAPEUTICS INC | 110 CANAL ST | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R44AI181242 | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | 001 | 2 | NIH | 11/8/2024 | $0 |
| | 2025 | 2025 | VERSATOPE THERAPEUTICS INC | 110 CANAL ST | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R44AI181242 | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | 000 | 2 | NIH | 11/1/2024 | $999,993 |
|
| Issue Date FY: 2024 ( Subtotal = $999,762 ) |
| | 2024 | 2024 | VERSATOPE THERAPEUTICS INC | 110 CANAL ST | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R44AI181242 | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | 000 | 1 | NIH | 12/8/2023 | $999,762 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | VERSATOPE THERAPEUTICS INC | 110 CANAL ST | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43AI149901 | Novel C. Difficile Vaccine Using Nano-vesicle Delivery System | 000 | 1 | NIH | 10/26/2021 | $0 |
| | 2022 | 2019 | VERSATOPE THERAPEUTICS INC | 110 CANAL ST | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43AI141055 | Multivalent influenza vaccine using recombinant outer membrane vesicles | 000 | 1 | NIH | 10/21/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $210,332 ) |
| | 2020 | 2020 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43AI149901 | Novel C. Difficile Vaccine Using Nano-vesicle Delivery System | 000 | 1 | NIH | 8/11/2020 | $299,928 |
| | 2020 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43IP001127 | Multivalent influenza vaccine using exosomes from probiotic E. coli | 04 | 1 | CDC | 9/1/2020 | -$2 |
| | 2020 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43IP001127 | Multivalent influenza vaccine using exosomes from probiotic E. coli | 02 | 1 | CDC | 2/28/2020 | -$121,504 |
| | 2020 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43IP001127 | Multivalent influenza vaccine using exosomes from probiotic E. coli | 03 | 1 | CDC | 3/25/2020 | $31,910 |
| | 2020 | 2018 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43AI136291 | Universal Influenza Vaccine | 000 | 1 | NIH | 1/23/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $449,974 ) |
| | 2019 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43AI141055 | Multivalent influenza vaccine using recombinant outer membrane vesicles | 000 | 1 | NIH | 4/4/2019 | $224,974 |
| | 2019 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43IP001127 | Multivalent influenza vaccine using exosomes from probiotic E. coli | 00 | 1 | CDC | 7/29/2019 | $225,000 |
| | 2019 | 2019 | VERSATOPE THERAPEUTICS, INC. | 110 CANAL ST FL 4 | LOWELL | MA | 01852-4574 | MIDDLESEX | USA | R43IP001127 | Multivalent influenza vaccine using exosomes from probiotic E. coli | 01 | 1 | CDC | 7/31/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $225,000 ) |
| | 2018 | 2018 | VERSATOPE THERAPEUTICS | 242 GROVE ST | LEXINGTON | MA | 02420-1016 | MIDDLESEX | USA | R43AI136291 | Universal Influenza Vaccine | 000 | 1 | NIH | 3/5/2018 | $225,000 |
|
|
